3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Tumor-Agnostic
4
Breast
4
Thoracic
2
Lymphoid
2
Gynecologic
2
CNS
2
Other solid neoplasm
1
Other hematologic neoplasm
1
Head & Neck
1
Endocrine
1
Conditions
Squamous Cell Carcinoma of Head and Neck
5
Uterine Cervical Neoplasms
1
Recurrence
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Ovarian Neoplasms
1
Neoplasms by Site
1
Neoplasms
1
Neoplasm Metastasis
1
Hereditary Sensory and Autonomic Neuropathies
1
Head and Neck Neoplasms
1
Gastrointestinal Stromal Tumors
1
Esophageal Squamous Cell Carcinoma
1
Endometrial Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Breast Diseases
1
Interventions
pembrolizumab
33
Cetuximab
16
Cisplatin
10
Radiotherapy
8
Paclitaxel
8
Docetaxel
8
atezolizumab
7
Fluorouracil
7
cemiplimab
6
Drug Therapy
6
budigalimab
5
Gemcitabine
5
Cyclophosphamide
5
Blood Specimen Collection
5
trametinib
4
Pemetrexed
4
Nivolumab
4
Magnetic Resonance Spectroscopy
4
Bleomycin
4
Bevacizumab
4
palbociclib
3
fludarabine
3
durvalumab
3
dabrafenib
3
avelumab
3
Trastuzumab
3
Oxaliplatin
3
Interleukin-2
3
Indocyanine Green
3
Immunotherapy
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms
×
ribociclib
×
Head & Neck
×
Clear all
NCT05768139
2026-06-04
PIKALO-1
Eli Lilly and Company
Phase 1/2
Recruiting
880 enrolled